Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study
2000; Lippincott Williams & Wilkins; Volume: 54; Issue: 9 Linguagem: Inglês
10.1212/wnl.54.9.1848
ISSN1526-632X
AutoresM. C. Walter, Hanns Lochmüller, Peter Reilich, Thomas Klopstock, Roman Huber, Manfred Hartard, Michael Hennig, D. Pongratz, Wolfgang Müller‐Felber,
Tópico(s)Genetic Neurodegenerative Diseases
ResumoArticle abstract The authors assessed the safety and efficacy of creatine monohydrate (Cr) in various types of muscular dystrophies in a double-blind, crossover trial. Thirty-six patients (12 patients with facioscapulohumeral dystrophy, 10 patients with Becker dystrophy, 8 patients with Duchenne dystrophy, and 6 patients with sarcoglycan-deficient limb girdle muscular dystrophy) were randomized to receive Cr or placebo for 8 weeks. There was mild but significant improvement in muscle strength and daily-life activities by Medical Research Council scales and the Neuromuscular Symptom Score. Cr was well tolerated throughout the study period.
Referência(s)